Santen Pharmaceutical Co Ltd
TSE:4536
Santen Pharmaceutical Co Ltd
Income from Continuing Operations
Santen Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Santen Pharmaceutical Co Ltd
TSE:4536
|
Income from Continuing Operations
¥27.5B
|
CAGR 3-Years
54%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥208.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥245.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥347.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥387.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
-¥57.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Santen Pharmaceutical Co Ltd
Glance View
Santen Pharmaceutical Co., Ltd., a cornerstone of Japan's robust pharmaceutical industry, has been relentlessly focused on improving eye health worldwide. Founded in 1890, the company began as a modest medicine retailer in Osaka, but over the decades, it has skillfully navigated the evolving healthcare landscape to become a global leader in ophthalmology. Today, Santen's enterprise is intricately woven with innovation and specialization, stretching its influence far beyond its Japanese roots. Its main thrust lies in the research, development, and commercialization of ophthalmic products tackling a comprehensive range of eye disorders, from dry eyes to age-related macular degeneration and glaucoma. By investing significantly in R&D, Santen maintains a robust pipeline of new treatments that continuously feeds into its growing portfolio, ensuring its offerings are at the forefront of medical advancements. Santen's business strategy thrives on leveraging its scientific expertise to not only create but also efficiently bring products to market across various continents. It operates through a well-crafted distribution network that spans Asia, Europe, and North America, tailoring its marketing and regulatory approaches to suit regional healthcare environments. This global footprint allows Santen to capture diverse markets, each with unique demands, thereby enhancing revenue streams. The firm's operational model also includes strategic partnerships and acquisitions, enhancing its research capabilities and expanding its market share to sustain profitability. Santen generates revenue primarily through the sale of innovative ophthalmic prescription drugs and over-the-counter products, supported by its strong relationships with healthcare professionals and continued expansion into emerging markets. The company’s focused strategy and commitment to eye health solutions position it as an indispensable player in the global healthcare industry.
See Also
What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
27.5B
JPY
Based on the financial report for Dec 31, 2024, Santen Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 27.5B JPY.
What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
2%
Over the last year, the Income from Continuing Operations growth was -1%. The average annual Income from Continuing Operations growth rates for Santen Pharmaceutical Co Ltd have been 54% over the past three years , -1% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet